Citations

Clear

4847 citation(s) found for "Tu, Eric".

Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21-Gene Recurrence Score
Loprinzi, Charles L. , Reynolds, Carol, Dueck, Amylou C. , Geiger, Xochiquetzal J., Carlson, Robert W. , Hobday, Timothy J. , Kamal, Arif H. , Ingle, James N. , Winer, Eric P. , Goetz, Matthew P. , Dueck, A. C.

Mayo Clinic

The Oncologist | September 21, 2011 | Volume: 16 | Issue: 10 | Pages: 1359-1366

10.1634/theoncologist.2011-0048 | PMID 21934103 Get It

Abstract Background. Half of all breast cancers are early stage, lymph node negative, and hormone receptor positive. A 21-gene (Oncotype DX®; Genomic Health, Inc., Redwood City, CA) recurrence score (RS) is prognostic for recurrence and predictive of chemotherapy benefit. We explored the ability of oncologists to predict the RS using standard prognostic criteria. Methods. Standard demographic and tumor prognostic criteria were obtained from patients with an available RS. Two academic pathologists provided tumor grade, histologic type, and hormone receptor status. Six academic oncologists predicted the RS category (low, intermediate, or high) and provided a recommendation for therapy. The oncologists were then given the actual RS and provided recommendations for therapy. Analysis for agreement was performed. Results. Thirty-one cases, including nine additional cases with variant pathology reads, were presented. There was substantial agreement in oncologists' ability to discriminate between true low or true intermediate and true high (κ = 0.75; p < .0001). Predictions between low and intermediate were not consistent. The most common discrepancies were predictions of a low RS risk when cases were true intermediate and predictions of an intermediate RS risk when cases were true low. The actual RS resulted in a change in the treatment recommendations in 19% of cases. Of the 186 scenarios and six oncologists in aggregate, five fewer chemotherapy recommendations resulted with the actual RS. Conclusions. Oncologists are able to differentiate between a low or intermediate RS and a high RS using standard prognostic criteria. However, provision of the actual RS changed the treatment recommendations in nearly 20% of cases, suggesting that the RS may reduce chemotherapy use. This effect was observed in particular in intermediate-risk cases. Prospective clinical trials are necessary to determine whether decisions based on the RS change outcomes.
Expanding DNA diagnostic panel testing: is more better?
Klee, Eric W. , Hoppman‐Chaney, Nicole L., Ferber, Matthew J.

Mayo Clinic

Expert Review of Molecular Diagnostics | September 8, 2011 | Volume: 11 | Issue: 7 | Pages: 703-709

10.1586/erm.11.58 | PMID 21902532 Get It

Species D Adenoviruses as Oncolytics against B-cell Cancers
Chen, Christopher Y. , Senac, Julien S., May, Shannon M., Jelinek, Diane F., Greipp, Philip R., Barry, Michael A. , Weaver, Eric A. , Witzig, Thomas E. , Weaver, Eric A , Barry, Michael A

Mayo Clinic

Clinical Cancer Research | September 3, 2011 | Volume: 17 | Issue: 21 | Pages: 6712-6722

10.1158/1078-0432.ccr-11-0968 | PMID 21890454 Get It

Abstract Purpose: Oncolytic viruses are self-amplifying anticancer agents that make use of the natural ability of viruses to kill cells. Adenovirus serotype 5 (Ad5) has been extensively tested against solid cancers, but less so against B-cell cancers because these cells do not generally express the coxsackie and adenoviral receptor (CAR). To determine whether other adenoviruses might have better potency, we “mined” the adenovirus virome of 55 serotypes for viruses that could kill B-cell cancers. Experimental Design: Fifteen adenoviruses selected to represent Ad species B, C, D, E, and F were tested in vitro against cell lines and primary patient B-cell cancers for their ability to infect, replicate in, and kill these cells. Select viruses were also tested against B-cell cancer xenografts in immunodeficient mice. Results: Species D adenoviruses mediated most robust killing against a range of B-cell cancer cell lines, against primary patient marginal zone lymphoma cells, and against primary patient CD138+ myeloma cells in vitro. When injected into xenografts in vivo, single treatment with select species D viruses Ad26 and Ad45 delayed lymphoma growth. Conclusions: Relatively unstudied species D adenoviruses have a unique ability to infect and replicate in B-cell cancers as compared with other adenovirus species. These data suggest these viruses have unique biology in B cells and support translation of novel species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res; 17(21); 6712–22. ©2011 AACR.
Endoscopic and surgical management of serrated colonic polyps
Léonard, Daniel , Dozois, Eric J. , Smyrk, Thomas C. , Suwanthanma, Weerapat , Baron, Todd H. , Cima, Robert R. , Larson, David W.

Mayo Clinic

British Journal of Surgery | September 1, 2011 | Volume: 98 | Issue: 12 | Pages: 1685-1694

10.1002/bjs.7654 | PMID 22034178 Get It

Abstract Background Serrated polyps are an inhomogeneous group of lesions that harbour precursors of colorectal cancer. Current research has been directed at further defining the histopathological characteristics of these lesions, but definitive treatment recommendations are unclear. The aim was to review the current literature regarding classification, molecular genetics and natural history of these lesions in order to propose a treatment algorithm for surgeons to consider. Methods The PubMed database was searched using the following search terms: serrated polyp, serrated adenoma, hyperplastic polyp, hyperplastic polyposis, adenoma, endoscopy, surgery, guidelines. Papers published between 1980 and 2010 were selected. Results Sixty papers met the selection criteria. Most authors agree that recommendations regarding endoscopic or surgical management should be based on the polyp's neoplastic potential. Polyps greater than 5 mm should be biopsied to determine their histology so that intervention can be directed accurately. Narrow-band imaging or chromoendoscopy may facilitate the detection and assessment of extent of lesions. Complete endoscopic removal of sessile serrated adenomas in the left or right colon is recommended. Follow-up colonoscopy is recommended in 2–6 months if endoscopic removal is incomplete. If the lesion cannot be entirely removed endoscopically, segmental colectomy is strongly recommended owing to the malignant potential of these polyps. Left-sided lesions are more likely to be pedunculated, making them more amenable to successful endoscopic removal. Conclusion Even though the neoplastic potential of certain subtypes of serrated polyp is heavily supported, further studies are needed to make definitive endoscopic and surgical recommendations.
Impact of apolipoprotein ɛ4–cerebrospinal fluid beta‐amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment
Chiang, Gloria , Tosun, Duygu , Schuff, Norbert, Truran‐Sacrey, Diana, Raptentsetsang, Sky, Reiman, Eric M. , Jagust, William J. , Harvey, Danielle , Beckett, Laurel , Gamst, Anthony, Aisen, Paul, Petersen, Ron, Weiner, Michael W. , Insel, Philip S. , Thompson, Paul M. , Jack, Clifford R. , Fox, Nick C. , Harvey, Danielle J , Tosun, Duygu

Mayo Clinic

Alzheimer's & Dementia | September 1, 2011 | Volume: 7 | Issue: 5 | Pages: 514-520

10.1016/j.jalz.2010.12.010 | PMID 21889115 Get It

BackgroundThe majority of studies relating amyloid pathology with brain volumes have been cross‐sectional. Apolipoprotein ɛ4 (APOE ɛ4), a genetic risk factor for Alzheimer's disease, is also known to be associated with hippocampal volume loss. No studies have considered the effects of amyloid pathology and APOE ɛ4 together on longitudinal volume loss.MethodsWe evaluated whether an abnormal level of cerebrospinal fluid beta‐amyloid (CSF Aβ) and APOE ɛ4 carrier status were independently associated with greater hippocampal volume loss over 1 year. We then assessed whether APOE ɛ4 status and CSF Aβ acted synergistically, testing the significance of an interaction term in the regression analysis. We included 297 participants: 77 cognitively normal, 144 with mild cognitive impairment (MCI), and 76 with Alzheimer's disease.ResultsAn abnormal CSF Aβ level was found to be associated with greater hippocampal volume loss over 1 year in each group. APOE ɛ4 was associated with hippocampal volume loss only in the cognitively normal and MCI groups. APOE ɛ4 carriers with abnormal CSF Aβ in the MCI group acted synergistically to produce disproportionately greater volume loss than noncarriers.ConclusionBaseline CSF Aβ predicts progression of hippocampal volume loss. APOE ɛ4 carrier status amplifies the degree of neurodegeneration in MCI. Understanding the effect of interactions between genetic risk and amyloid pathology will be important in clinical trials and our understanding of the disease process.
Normal pressure hydrocephalus
Klassen, Bryan T. , Ahlskog, J. Eric

Mayo Clinic

Neurology | August 22, 2011 | Volume: 77 | Issue: 12 | Pages: 1119-1125

10.1212/wnl.0b013e31822f02f5 | PMID 21849644 Get It

Minimally Invasive Surgery for Colorectal Cancer: Past, Present, and Future
Holder‐Murray, Jennifer , Dozois, Eric J.

Mayo Clinic

International Journal of Surgical Oncology | August 18, 2011 | Volume: 2011 | Issue: No issue available | Pages: 1-8

10.1155/2011/490917 | PMID 22312511 Get It

A rapid progression from conventional open surgery to minimally invasive approaches in the surgical management of colorectal cancer has occurred over the last 2 decades. Initial concerns that this new approach was oncologically inferior to open surgery were ultimately refuted when several prospective randomized trials concluded that laparoscopic colectomy could achieve similar oncologic outcomes to open surgery. On the contrary, level 1 data has not yet matured regarding the oncologic safety of minimally invasive approaches for rectal cancer. We review the published literature pertaining to the evolution of minimally invasive techniques used to treat colorectal cancer surgery, including barriers to adoption, and the prospects for future advances related to innovative techniques.
Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer
Stevens, Kristen N., Vachon, Celine M. , Slager, Susan, Lesnick, Timothy G. , Olswold, Curtis, Fasching, Peter A. , Miron, Penelope , Eccles, Diana , Carpenter, Jane, Winqvist, Robert , Brauch, Hiltrud , Schmidt, Marjanka K. , Cox, Angela , Cross, Simon S. , Sawyer, Elinor J. , Hartmann, Arndt, Beckmann, Matthias W. , Schulz-Wendtland, Rüdiger, Ekici, Arif B. , Tapper, William , Gerty, Susan M. , Durcan, Lorraine , Graham, Nikki , Hein, Rebecca, Nickels, Stephan, Flesch‐Janys, Dieter, Heinz, Judith , Sinn, Hans‐Peter , Konstantopoulou, Irene , Pectasides, Dimitrios , Dimopoulos, Athanasios M., Clarke, Christine L. , Balleine, Rosemary L. , Fredericksen, Zachary, Diasio, Robert B. , Ross, Eric A. , Weaver, JoEllen , Rüdiger, Thomas , Dünnebier, Thomas, Ademuyiwa, Foluso O. , Kulkarni, Swati , Pylkäs, Katri , Jukkola‐Vuorinen, Arja , Ko, Yon‐Dschun, Limbergen, Erik Van, Janssen, Hilde, Peto, Julian , Fletcher, Olivia , Giles, Graham G. , Baglietto, Laura , Verhoef, Senno, Tomlinson, Ian , Kosma, Veli‐Matti , Greco, Dario , Blomqvist, Carl , Irwanto, Astrid , Liu, Jianjun , Blows, Fiona M., Dawson, Sarah‐Jane , Margolin, Sara , Mannermaa, Arto, Martin, Nicholas G. , Montgomery, Grant W. , Lambrechts, Diether , dos‐Santos‐Silva, Isabel , Severi, Gianluca , Hamann, Ute, Easton, Douglas F., Chang‐Claude, Jenny , Yannoukakos, Drakoulis , Nevanlinna, Heli , Dimopoulos, Meletios Α. , Purrington, Kristen S. , Lambrechts, Diether , Vachon, Celine M. , Lee, Adam M. , Godwin, Andrew K. , Ambrosone, Christine B. , Fostira, Florentia , Dimopoulos, Athanasios M., Fountzilas, George , Olson, Janet E. , Pathak, Harsh B. , Försti, Asta , Beesley, Jonathan , Mannermaa, Arto, Pharoah, Paul D.P. , Wang, Xianshu , Couch, Fergus J. , Nevanlinna, H , Lambrechts, Diether , Giles, Graham G , Eccles, Diana , Dimopoulos, Meletios A , Konstantopoulou, Irene , Martin, Nicholas G , Sinn, Peter , Lambrechts, Diether , Cox, Angela , Schmidt, Marjanka K , Severi, Gianluca , Ekici, Arif B , Ademuyiwa, Foluso O , Pylkäs, Katri , Yannoukakos, Drakoulis , Baglietto, Laura , Fletcher, Olivia , Purrington, Kristen S , Brauch, Hiltrud , Sawyer, Elinor J , Liu, Jing

Mayo Clinic

Cancer Research | August 15, 2011 | Volume: 71 | Issue: 19 | Pages: 6240-6249

10.1158/0008-5472.can-11-1266 | PMID 21844186 Get It

Abstract Triple-negative breast cancers are an aggressive subtype of breast cancer with poor survival, but there remains little known about the etiologic factors that promote its initiation and development. Commonly inherited breast cancer risk factors identified through genome-wide association studies display heterogeneity of effect among breast cancer subtypes as defined by the status of estrogen and progesterone receptors. In the Triple Negative Breast Cancer Consortium (TNBCC), 22 common breast cancer susceptibility variants were investigated in 2,980 Caucasian women with triple-negative breast cancer and 4,978 healthy controls. We identified six single-nucleotide polymorphisms, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 (19p13.1), and rs8100241 (19p13.1), significantly associated with the risk of triple-negative breast cancer. Together, our results provide convincing evidence of genetic susceptibility for triple-negative breast cancer. Cancer Res; 71(19); 6240–9. ©2011 AACR.
Polymyalgia Rheumatica and Giant Cell Arteritis: Management of Two Diseases of the Elderly
Dejaco, Christian , Duftner, Christina , Matteson, Eric L. , Schirmer, Michael , Dasgupta, Bhaskar , Dejaco, Christian

Mayo Clinic

Aging Health | August 12, 2011 | Volume: 7 | Issue: 4 | Pages: 633-645

10.2217/ahe.11.50 Get It

Adverse Effects in Hospice Patients with Chronic Kidney Disease Receiving Hydromorphone
Paramanandam, Gobi, Prommer, Eric , Schwenke, Dawn C.

Mayo Clinic

Journal of Palliative Medicine | August 8, 2011 | Volume: 14 | Issue: 9 | Pages: 1029-1033

10.1089/jpm.2011.0103 | PMID 21823925 Get It